Adagio Medical Announces CE Mark approval of VT Cryoablation System, Plans for Immediate Commercialization in Select European Centers
Adagio Medical, Inc., a leading innovator in catheter ablation technologies for ventricular tachycardia ("VT") and atrial fibrillation ("AF"), today announced CE Mark approval of its ultra-low temperature cryoablation ("ULTC") system for the treatment of monomorphic ventricular tachycardia. The system consists of the upgraded cryoablation console, also capable of supporting atrial ablation procedures using commercially available iCLAS™ catheters, and the vCLA...
Source: yahoo.com